Neumora Therapeutics, Inc. Common StockNMRANASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
4.64%
↓ 94% below average
Average (19q)
74.10%
Historical baseline
Range
High:1473.99%
Low:-88.97%
Volatility
2109.3%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 4.64% |
| Q2 2025 | -25.75% |
| Q1 2025 | 13.59% |
| Q4 2024 | -24.28% |
| Q3 2024 | 24.68% |
| Q2 2024 | 6.27% |
| Q1 2024 | 17.74% |
| Q4 2023 | -6.58% |
| Q3 2023 | 26.95% |
| Q2 2023 | 11.14% |
| Q1 2023 | 25.35% |
| Q4 2022 | 4.32% |
| Q3 2022 | -4.16% |
| Q2 2022 | -33.06% |
| Q1 2022 | 85.89% |
| Q4 2021 | -88.97% |
| Q3 2021 | 1473.99% |
| Q2 2021 | -5.29% |
| Q1 2021 | -24.49% |
| Q4 2020 | 0.00% |